Citations

Clear

3942 citation(s) found for "To, Van".

Multicenter Survival Analysis and Application of an Olfactory Neuroblastoma Staging Modification Incorporating Hyams Grade
Champagne, Pierre‐Olivier , Chan, Erik, Ciporen, Jeremy , Chaskes, Mark B., Fernandez‐Miranda, Juan C. , Gardner, Paul A. , Hwang, Peter H. , Ji, Keven Seung Yong , Kalyvas, Aristotelis , Kong, Keonho A., McMillan, Ryan A. , O’Byrne, Jamie, Patel, Chirag , Patel, Zara M. , Celda, María Peris, Sanusi, Olabisi , Thorp, Brian D. , Young, Sarah C. , Zenonos, Georgios A. , Zwagerman, Nathan T. , McMillan, Ryan, O'Byrne, Jamie, Peris Celda, Maria, Pinheiro-Neto, Carlos, Patel, Zara , Hwang, Peter H , Choby, Garret , Geltzeiler, Mathew , Almeida, João Paulo , Nayak, Jayakar V. , Pinheiro‐Neto, Carlos , Snyderman, Carl H , Gompel, Jamie J. Van , Wang, Eric W

Mayo Clinic

JAMA Otolaryngology–Head & Neck Surgery | August 3, 2023 | Volume: 149 | Issue: 9 | Pages: 837

10.1001/jamaoto.2023.1939 | PMID 37535372 Get It

ImportanceCurrent olfactory neuroblastoma (ONB) staging systems inadequately delineate locally advanced tumors, do not incorporate tumor grade, and poorly estimate survival and recurrence.ObjectiveThe primary aims of this study were to (1) examine the clinical covariates associated with survival and recurrence of ONB in a modern-era multicenter cohort and (2) incorporate Hyams tumor grade into existing staging systems to assess its ability to estimate survival and recurrence.Design, Setting, and ParticipantsThis retrospective, multicenter, case-control study included patients with ONB who underwent treatment between January 1, 2005, and December 31, 2021, at 9 North American academic medical centers.InterventionStandard-of-care ONB treatment.Main Outcome and MeasuresThe main outcomes were overall survival (OS), disease-free survival (DFS), and disease-specific survival (DSS) as C statistics for model prediction.ResultsA total of 256 patients with ONB (mean [SD] age, 52.0 [15.6] years; 115 female [44.9%]; 141 male [55.1%]) were included. The 5-year rate for OS was 83.5% (95% CI, 78.3%-89.1%); for DFS, 70.8% (95% CI, 64.3%-78.0%); and for DSS, 94.1% (95% CI, 90.5%-97.8%). On multivariable analysis, age, American Joint Committee on Cancer (AJCC) stage, involvement of bilateral maxillary sinuses, and positive margins were associated with OS. Only AJCC stage was associated with DFS. Only N stage was associated with DSS. When assessing the ability of staging systems to estimate OS, the best-performing model was the novel modification of the Dulguerov system (C statistic, 0.66; 95% CI, 0.59-0.76), and the Kadish system performed most poorly (C statistic, 0.57; 95% CI, 0.50-0.63). Regarding estimation of DFS, the modified Kadish system performed most poorly (C statistic, 0.55; 95% CI, 0.51-0.66), while the novel modification of the AJCC system performed the best (C statistic, 0.70; 95% CI, 0.66-0.80). Regarding estimation of DSS, the modified Kadish system was the best-performing model (C statistic, 0.79; 95% CI, 0.70-0.94), and the unmodified Kadish performed the worst (C statistic, 0.56; 95% CI, 0.51-0.68). The ability for novel ONB staging systems to estimate disease progression across stages was also assessed. In the novel Kadish staging system, patients with stage VI disease were approximately 7 times as likely to experience disease progression as patients with stage I disease (hazard ratio [HR], 6.84; 95% CI, 1.60-29.20). Results were similar for the novel modified Kadish system (HR, 8.99; 95% CI, 1.62-49.85) and the novel Dulguerov system (HR, 6.86; 95% CI, 2.74-17.18).Conclusions and RelevanceThe study findings indicate that 5-year OS for ONB is favorable and that incorporation of Hyams grade into traditional ONB staging systems is associated with improved estimation of disease progression.
Prospective, randomized, double-blind phase 2B trial of the TLPO and TLPLDC vaccines to prevent recurrence of resected stage III/IV melanoma: a prespecified 36-month analysis
Carpenter, Elizabeth Lee, Decar, Spencer Van , McCarthy, Patrick M. , Vreeland, Timothy J. , Valdera, Franklin, Tiwari, Ankur, Hale, Diane F. , Bohan, Phillip Kemp, Hickerson, Annelies T. , Smolinsky, Todd , Thomas, Katryna, Cindass, Jessica L., Hyngstrom, John , Berger, Adam C. , Shaheen, Montaser , Yu, Xianzhong, Wagner, Thomas E., Faries, Mark B. , Peoples, George E. , Van Decar, Spencer , McCarthy, Patrick , Vreeland, Timothy J , Jakub, James, Adams, Alexandra M. , O’Shea, Anne E. , Chick, Robert C. , Clifton, Guy T. , Bohan, Phillip M. Kemp , Jakub, James W. , Sussman, Jonathan

Mayo Clinic

Journal for ImmunoTherapy of Cancer | August 3, 2023 | Volume: 11 | Issue: 8 | Pages: e006665

10.1136/jitc-2023-006665 | PMID 37536936 Get It

Background The tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine is made by ex vivo priming matured autologous dendritic cells (DCs) with yeast cell wall particles (YCWPs) loaded with autologous tumor lysate (TL). The tumor lysate, particle only (TLPO) vaccine uses autologous TL-loaded YCWPs coated with silicate for in vivo DC loading. Here we report the 36-month prespecified analyses of this prospective, randomized, double-blind trial investigating the ability of the TLPO and TLPLDC (±granulocyte-colony stimulating factor (G-CSF)) vaccines to prevent melanoma recurrence in high-risk patients. Methods Patients with clinically disease-free stage III/IV melanoma were randomized 2:1 initially to TLPLDC versus placebo (n=124) and subsequently TLPO versus TLPLDC (n=63). All patients were randomized and blinded; however, the placebo control arm was replaced in the second randomization scheme with another novel vaccine; some analyses in this paper therefore reflect a combination of the two randomization schemes. Patients receiving the TLPLDC vaccine were further divided by their method of DC harvest (with or without G-CSF pretreatment); this was not randomized. The use of standard of care checkpoint inhibitors was not stratified between groups. Safety was assessed and Kaplan-Meier and log-rank analyses compared disease-free (DFS) and overall survival (OS). Results After combining the two randomization processes, a total of 187 patients were allocated between treatment arms: placebo (n=41), TLPLDC (n=103), or TLPO (n=43). The allocation among arms created by the addition of patients from the two separate randomization schemes does not reflect concurrent randomization among all treatment arms. TLPLDC was further divided by use of G-CSF in DC harvest: no G-CSF (TLPLDC) (n=47) and with G-CSF (TLPLDC+G) (n=56). Median follow-up was 35.8 months. Only two patients experienced a related adverse event ≥grade 3, one each in the TLPLDC+G and placebo arms. DFS was 27.2% (placebo), 55.4% (TLPLDC), 22.9% (TLPLDC+G), and 60.9% (TLPO) (p<0.001). OS was 62.5% (placebo), 93.6% (TLPLDC), 57.7% (TLPLDC+G), and 94.6% (TLPO) (p=0.002). Conclusions The TLPO and TLPLDC (without G-CSF) vaccines were associated with improved DFS and OS in this clinical trial. Given production and manufacturing advantages, the efficacy of the TLPO vaccine will be confirmed in a phase 3 trial. Trial registration number NCT02301611 .
Next-Generation Bone Stimulation: Doubling Down on Bone Anabolics
Wijnen, André J. van , Dashti, Parisa , van Wijnen, Andre J

Mayo Clinic

Journal of Bone and Joint Surgery | August 2, 2023 | Volume: 105 | Issue: 15 | Pages: e38

10.2106/jbjs.23.00550 | PMID 37530724 Get It

Treatment outcome of metastasis to the pituitary gland: a case series of 21 patients with pathological diagnosis
Hong, Sukwoo , Atkinson, John L. D., Erickson, Dana , Kizilbash, Sani H. , Little, Jason T. , Kizilbash, Sani H , Routman, David M. , Gompel, Jamie J. Van

Mayo Clinic

Neurosurgical Focus | August 1, 2023 | Volume: 55 | Issue: 2 | Pages: E13

10.3171/2023.5.focus23185 | PMID 37527679 Get It

OBJECTIVE The aim of this study was to report the treatment course of histologically confirmed metastases to the pituitary gland (pituitary metastasis). METHODS The Mayo data explorer was used to find patients with pituitary metastasis. Twenty-one patients were identified between the years 2001 and 2021, and their data were retrospectively collected. RESULTS The most common primary cancer origin was lung in men (45%) and breast in women (33%). The median age was 66 years (IQR 56–68 years). Patients presented with headache (67% [14/21]), vision problems (86% [18/21]), anterior hypopituitarism (71% [15/21]), and arginine vasopressin deficiency (38% [8/21]). Pituitary metastases were found before the diagnosis of the primary cancer in 5 patients (24%). The mean ± SD tumor size was 2.0 ± 0.7 cm, and 90% (19/21) presented as a solitary pituitary mass with no other intracranial metastatic lesions. Common radiological features were pituitary stalk thickening (90% [19/21]), cavernous sinus involvement (71% [15/21]), and constriction at the diaphragma sellae (52% [11/21]). Transsphenoidal surgery was performed in 20 patients, and subtotal resection was most frequently attained (76% [16/21]). Fourteen patients (67%) had adjuvant radiation therapy, and 15 patients (71%) were treated with systemic therapy. The median time from surgery to the initiation of radiation therapy was 16 days (IQR 11–21 days), and that from surgery to the initiation of systemic therapy was 5.0 months (IQR 1.5–14 months). During management, headaches improved in 57% (8/14) and vision problems improved in 61% (11/18) of cases; new hypopituitarism occurred in 5 patients. Six patients developed recurrence, and the median progression-free survival was 24 months (95% CI 5.4–43 months). After recurrence, 1 patient with adenoid cystic carcinoma was treated with rescue radiotherapy twice, and 4 patients responded well to systemic therapy. The median overall survival (OS) was 25 months (95% CI 7.1–43 months). The mean OS was better in patients with neuroendocrine lung tumor (261 months) and papillary thyroid carcinoma (80 months) and worse in patients with small cell lung cancer (4 months) and unknown origin (5 months). CONCLUSIONS Surgery with or without adjuvant radiotherapy is effective for mass reduction, rapid symptomatic improvement of vision and headaches, and definitive diagnosis. Even after local tumor control failure, some patients still benefit from radiation and/or systemic therapy.
Recommendations for Standardizing MRI-based Evaluation of Perianal Fistulizing Disease Activity in Pediatric Crohn’s Disease Clinical Trials
Crowley, Eileen , Ma, Christopher , Guizzetti, Leonard, Lewindon, Peter , Gee, Michael S. , Hyams, Jeffrey S. , Rosen, Michael J. , Allmen, Daniel von, Overstraeten, Anthony de Buck van , Shackelton, Lisa M. , Rémillard, Julie, Schleicher, Lauren S., Rimola, Jordi , Taylor, Stuart A. , Church, Peter , Feagan, Brian G. , Jairath, Vipul , Jairath, Vipul , Jairath, Vipul , Hyams, Jeffrey S , Shackelton, Lisa M , Rimola, Jordi , Ma, C , Jairath, V , Jairath, V , Jairath, Vipul , Zou, Guangyong , Gee, Michael Stanley , Dillman, Jonathan R , Fletcher, Joel G. , Griffiths, Anne Marie , Greer, Mary‐Louise C.

Mayo Clinic

Inflammatory Bowel Diseases | July 31, 2023 | Volume: 30 | Issue: 3 | Pages: 357-369

10.1093/ibd/izad134 | PMID 37524088 Get It

Abstract Background Perianal fistulas and abscesses occur commonly as complications of pediatric Crohn’s disease (CD). A validated imaging assessment tool for quantification of perianal disease severity and activity is needed to evaluate treatment response. We aimed to identify magnetic resonance imaging (MRI)-based measures of perianal fistulizing disease activity and study design features appropriate for pediatric patients. Methods Seventy-nine statements relevant to MRI-based assessment of pediatric perianal fistulizing CD activity and clinical trial design were generated from literature review and expert opinion. Statement appropriateness was rated by a panel (N = 15) of gastroenterologists, radiologists, and surgeons using modified RAND/University of California Los Angeles appropriateness methodology. Results The modified Van Assche Index (mVAI) and the Magnetic Resonance Novel Index for Fistula Imaging in CD (MAGNIFI-CD) were considered appropriate instruments for use in pediatric perianal fistulizing disease clinical trials. Although there was concern regarding the use of intravascular contrast material in pediatric patients, its use in clinical trials was considered appropriate. A clinically evident fistula tract and radiologic disease defined as at least 1 fistula or abscess on pelvic MRI were considered appropriate trial inclusion criteria. A coprimary clinical and radiologic end point and inclusion of a patient-reported outcome were also considered appropriate. Conclusion Outcomes of treatment of perianal fistulizing disease in children must include MRI. Existing multi-item measures, specifically the mVAI and MAGNIFI-CD, can be adapted and used for children. Further research to assess the operating properties of the indices when used in a pediatric patient population is ongoing.
7T MRI and Intraoperative Ultrasound-Guided Endoscopic Endonasal Resection of 3T MRI-Negative Pituitary Corticotroph Microadenoma: 2-Dimensional Operative Video
McGrath, Hari , Plitt, Aaron , Gompel, Jamie J. Van , Plitt, Aaron R , Bancos, Irina , Choby, Garret , Van Gompel, Jamie J , Bancos, Irina , Choby, Garret

Mayo Clinic

Operative Neurosurgery | July 31, 2023 | Volume: 25 | Issue: 5 | Pages: e290-e290

10.1227/ons.0000000000000846 | PMID 37523622 Get It

Advancing specificity in delirium: The delirium subtyping initiative
Bowman, Emily M L , Fiest, Kirsten M. , Girard, Timothy D. , Jackson, Thomas , LaHue, Sara C. , MacLullich, Alasdair M. J. , McAuley, Daniel F. , Potter, Kelly , Sinha, Pratik , Slooter, Arjen J. C. , Sweeney, Aoife , Tieges, Zoë , Dellen, Edwin van , Wilcox, M. Elizabeth , Cunningham, Emma , Lindroth, Heidi L., Girard, Timothy D , MacLullich, Alasdair M J , Slooter, Arjen J C , Brummel, Nathan E. , Caplan, Gideon A. , Cunningham, Colm M. , Evered, Lisbeth Anne , Lindroth, Heidi , Oh, Esther S , Oldham, Mark , Page, Valérie , Pandharipande, Pratik , Zetterberg, Henrik

Mayo Clinic

Alzheimer's & Dementia | July 31, 2023 | Volume: 20 | Issue: 1 | Pages: 183-194

10.1002/alz.13419 | PMID 37522255 Get It

AbstractBACKGROUNDDelirium, a common syndrome with heterogeneous etiologies and clinical presentations, is associated with poor long‐term outcomes. Recording and analyzing all delirium equally could be hindering the field's understanding of pathophysiology and identification of targeted treatments. Current delirium subtyping methods reflect clinically evident features but likely do not account for underlying biology.METHODSThe Delirium Subtyping Initiative (DSI) held three sessions with an international panel of 25 experts.RESULTSMeeting participants suggest further characterization of delirium features to complement the existing Diagnostic and Statistical Manual of Mental Disorders Fifth Edition Text Revision diagnostic criteria. These should span the range of delirium‐spectrum syndromes and be measured consistently across studies. Clinical features should be recorded in conjunction with biospecimen collection, where feasible, in a standardized way, to determine temporal associations of biology coincident with clinical fluctuations.DISCUSSIONThe DSI made recommendations spanning the breadth of delirium research including clinical features, study planning, data collection, and data analysis for characterization of candidate delirium subtypes.Highlights Delirium features must be clearly defined, standardized, and operationalized. Large datasets incorporating both clinical and biomarker variables should be analyzed together. Delirium screening should incorporate communication and reasoning.
Plasma‐derived biomarkers of Alzheimer's disease and neuropsychiatric symptoms: A community‐based study
Krell‐Roesch, Janina , Syrjanen, Jeremy A. , Kremers, Walter K. , Dage, Jeffrey L. , Fields, Julie A. , Petersen, Ronald C. , Vassilaki, Maria , Geda, Yonas E. , Zaniletti, Isabella, Geda, Yonas E , Kremers, Walter K , Dage, Jeffrey L , Zaniletti, Isabella , Algeciras‐Schimnich, Alicia , Harten, Argonde C. van , Knopman, David S. , Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring | July 31, 2023 | Volume: 15 | Issue: 3 | Pages: No page available

10.1002/dad2.12461 | PMID 37529120 Get It

AbstractINTRODUCTIONWe examined associations between plasma‐derived biomarkers of Alzheimer's disease (AD) and neuropsychiatric symptoms (NPS) in community‐dwelling older adults.METHODSCross‐sectional study involving 1005 persons ≥50 years of age (mean 74 years, 564 male, 118 cognitively impaired), who completed plasma‐derived biomarker (amyloid beta 42 [Aβ42]/Aβ40, phosphorylated tau 181 [p‐tau181], p‐tau217, total tau [t‐tau], neurofilament light [NfL]), and NPS assessment.RESULTSP‐tau181 (odds ratio [OR] 2.06, 95% confidence interval [CI] 1.41–3.00, p < 0.001), p‐tau217 (OR 1.70, 95% CI 1.10–2.61, p = 0.016), and t‐tau (OR 1.44, 95% CI 1.08–1.92, p = 0.012) were associated with appetite change. We also found that p‐tau181 and p‐tau217 were associated with increased symptoms of agitation (OR 1.93, 95% CI 1.20–3.11, p = 0.007 and OR 2.04, 95% CI 1.21–3.42, p = 0.007, respectively), and disinhibition (OR 2.39, 95% CI 1.45–3.93, p = 0.001 and OR 2.30, 95% CI 1.33–3.98, p = 0.003, respectively). Aβ42/Aβ40 and NfL were not associated with NPS.CONCLUSIONHigher plasma‐derived p‐tau181 and p‐tau217 levels are associated with increased symptoms of appetite change, agitation, and disinhibition. These findings may support the validity of plasma tau biomarkers for predicting behavioral symptoms that often accompany cognitive impairment.HIGHLIGHTS We studied 1005 community‐dwelling persons aged ≥ 50 years Higher plasma tau levels are associated with increased neuropsychiatric symptoms Aβ42/Aβ40 and NfL are not associated with neuropsychiatric symptoms Clinicians should treat neuropsychiatric symptoms in persons with high plasma‐derived tau
Decoding single and paired phonemes using 7T functional MRI
Vitória, Maria Araújo , Fernandes, Francisco Guerreiro , Raemaekers, Mathijs , Boom, Max van den , Ramsey, Nick F.

Mayo Clinic

No container title available | July 28, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3200600/v1 Get It

Abstract Several studies have shown that mouth movements related to the pronunciation of individual phonemes are represented in the sensorimotor cortex. This would theoretically allow for brain computer interfaces that are capable of decoding continuous speech by training classifiers based on the activity in the sensorimotor cortex related to the production of individual phonemes. To address this, we investigated the decodability of trials with individual and paired phonemes (pronounced consecutively with one second interval) using activity in the sensorimotor cortex. Fifteen participants pronounced 3 different phonemes and 3 combinations of two of the same phonemes in a 7T functional MRI experiment. We confirmed that support vector machine (SVM) classification of single and paired phonemes was possible. Importantly, by combining classifiers trained on single phonemes, we were able to classify paired phonemes with an accuracy of 53% (33% chance level), demonstrating that activity of isolated phonemes is present and distinguishable in combined phonemes. A SVM searchlight analysis showed that the phoneme representations are widely distributed in the ventral sensorimotor cortex. These findings provide insights about the neural representations of single and paired phonemes. Furthermore, it supports the notion that speech BCI may be feasible based on machine learning algorithms trained on individual phonemes using intracranial electrode grids.
Effect of Autologous Conditioned Plasma Injections in Patients With Knee Osteoarthritis
Korpershoek, Jasmijn V. , Kester, Esmee C., Egmond, Nienke van , Saris, Daniël B.F. , Korpershoek, Jasmijn V , Vonk, Luciënne A. , Filardo, Giuseppe , Custers, Roel J.H.

Mayo Clinic

Orthopaedic Journal of Sports Medicine | July 28, 2023 | Volume: 11 | Issue: 7 | Pages: No page available

10.1177/23259671231184848 | PMID 37529531 Get It

Background: Autologous conditioned plasma (ACP) is a commercially available platelet concentrate with promising results from clinical trials. Purpose: To evaluate the clinical outcome after 3 consecutive injections of ACP in patients with knee osteoarthritis (OA) and study the influence of ACP composition and different patient factors as predictors of treatment effect. Study Design: Case series; Level of evidence, 4. Methods: This prospective case series included 260 patients (307 knees) who received ACP treatment for knee OA. The mean patient age was 51 ± 10 years. Improvement up to 12 months’ follow-up was measured using the Knee injury and Osteoarthritis Outcome Score (KOOS). ACP composition was analyzed in 100 patients. The predictive value of age, sex, history of knee trauma, Kellgren-Lawrence OA grade, body mass index, and ACP composition was evaluated using generalized estimating equations. Results: The mean overall KOOS improved from 38 ± 14 at baseline to 45 ± 18 at 3 months, 45 ± 18 at 6 months, and 43 ± 18 at 12 months (all P < .05); 40% of patients achieved an improvement above the minimal clinically important difference (MCID) of 8 after 6 months and 33% after 12 months. The variation in ACP composition did not correlate with KOOS ( P > .05). Older age led to a greater clinical benefit (β = 0.27; P = .05), whereas bilateral treatment predicted worse outcomes (β = –5.6; P < .05). Conclusion: The improvement in KOOS after treatment with ACP did not reach the MCID in most study patients. Older age was a predictor for better outcomes. The composition of ACP varied between patients but did not predict outcomes within the evaluated range. The study findings show the limited benefit of ACP treatment for knee OA and call for caution with routine use in clinical practice.